Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl


Preferences help
enabled [disable] Abstract
Number of results
2022 | 168 | 57-68

Article title

A rapid sensitive and an efficient method development and validation of carfilzomib by UV-Vis spectrophotometric analysis


Title variants

Languages of publication



People are focusing their attention on personal health in the current situation. Medicine has an important function to play in maintaining our health. Researchers developed various compounds to cure important health issues such as cancer, diabetes, and tuberculosis, among others. We are focusing on Carfilzomib, an anti-cancer drug supplement. The present work discusses the development and validation of the UV Spectrophotometric method for carfilzomib. Simple, specific, and economic purposes UV spectrophotometric method has been developed using the methanol as a diluent to the estimation of carfilzomib in vial formulation. The max of carfilzomib was found to be 203 nm. The linearity in the concentration range 4-16 g/ml was founded to have a good correlation coefficient (R2 = 0.9952). The accuracy was between (99.4-101.2%), The LOD and LOQ are 0.00156 g/ml and 0.00472 g/ml respectively.






Physical description


  • Department of Chemistry, Saurashtra University, Rajkot - 360005, Gujarat, India
  • Department of Chemistry, Saurashtra University, Rajkot - 360005, Gujarat, India
  • B. K. Mody Government Pharmacy College, Rajkot - 360005, Gujarat, India
  • Department of Chemistry, Saurashtra University, Rajkot - 360005, Gujarat, India


  • [1] Wang, H.; Naghavi, M.; Allen, C.; Barber, R.M.; Bhutta, Z.A.; Carter, A.; Casey, D.C.; Charlson, F.J.; Chen, A.Z.; Coates, M.M. Global, Regional, and National Life Expectancy, All-Cause Mortality, and Cause-Specific Mortality for 249 Causes of Death, 1980–2015: A Systematic Analysis for the Global Burden of Disease Study 2015. The Lancet, 388 (2016) 1459–1544
  • [2] Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.; Forman, D.; Bray, F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] Lyon. Fr. Internafional Agency Res. Cancer, 2013.
  • [3] Shewach, D.S.; Kuchta, R.D. Introduction to Cancer Chemotherapeutics. Chem. Rev. 109 (2009) 2859–2861
  • [4] Zahreddine, H.; Borden, K. Mechanisms and Insights into Drug Resistance in Cancer. Front. Pharmacol. 4 (2013) 28
  • [5] Min, J.S.; Kim, J.; Kim, J.H.; Kim, D.; Zheng, Y.F.; Park, J.E.; Lee, W.; Bae, S.K. Quantitative Determination of Carfilzomib in Mouse Plasma by Liquid Chromatography–Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study. J. Pharm. Biomed. Anal. 146 (2017) 341–346
  • [6] Siegel, D.S.; Martin, T.; Wang, M.; Vij, R.; Jakubowiak, A.J.; Lonial, S.; Trudel, S.; Kukreti, V.; Bahlis, N.; Alsina, M. A Phase 2 Study of Single-Agent Carfilzomib (PX-171-003-A1) in Patients with Relapsed and Refractory Multiple Myeloma. Blood J. Am. Soc. Hematol. 120 (2012) 2817–2825
  • [7] Sestak, V.; Roh, J.; Klepalova, L.; Kovarikova, P. A UHPLC-UV-QTOF Study on the Stability of Carfilzomib, a Novel Proteasome Inhibitor. J. Pharm. Biomed. Anal., 124 (2016) 365–373
  • [8] Gopireddy, R.R.; Maruthapillai, A.; Devikala, S.; Tamilselvi, M.; Selvi, J.A.; Mahapatra, S. DoE Approach: A Validated Stability Indicating RP-HPLC Method Development for the Separation of Diasteromeric Analogs and Process Impurities of Carfilzomib. 2nd Int. Conf. Recent Adv. Mater. Chem. 14-16 Febr. 14 (2019) 514–531
  • [9] Fu, L.; Liu, G.; Zhao, D.; Yuan, L.; Lu, K. Interaction of Two Peptide Drugs with Biomacromolecules Analyzed by Molecular Docking and Multi-Spectroscopic Methods. Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 255 (2021) 119673

Document Type


Publication order reference


YADDA identifier

JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.